Search

Your search keyword '"Clerici, Thierry"' showing total 21 results
Start Over Author "Clerici, Thierry"
21 results on '"Clerici, Thierry"'

4. No evidence of somatic FGFR3 mutation in various types of carcinoma

Author

Karoui, Mehdi, Hofmann-Radvanyi, Hélène, Zimmermann, Ute, Couvelard, Anne, Degott, Claude, Faridoni-Laurens, Laetitia, Ahomadegbe, Jean-Charles, Gazzeri, Sylvie, Brambilla, Elisabeth, Clerici, Thierry, Charbonnier, Peggy, Tresallet, Christophe, Mitry, Emmanuel, Penna, Christophe, Rougier, Philippe, Boileau, Catherine, Thiery, Jean-Paul, Nordlinger, Bernard, Franc, Brigitte, and Radvanyi, François

Published
2001
Full Text
View/download PDF

8. Variations of BRAF mutant allele percentage in melanomas

Author

Hélias-Rodzewicz, Zofia, primary, Funck-Brentano, Elisa, additional, Baudoux, Laure, additional, Jung, Chan Kwon, additional, Zimmermann, Ute, additional, Marin, Cristi, additional, Clerici, Thierry, additional, Le Gall, Catherine, additional, Peschaud, Frédérique, additional, Taly, Valérie, additional, Saiag, Philippe, additional, and Emile, Jean-François, additional

Published
2015
Full Text
View/download PDF

12. Detection of BRAF p.V600E Mutations in Melanomas

Author

Colomba, Emeline, primary, Hélias-Rodzewicz, Zofia, additional, Von Deimling, Andreas, additional, Marin, Cristi, additional, Terrones, Nathalie, additional, Pechaud, Dominique, additional, Surel, Sylvie, additional, Côté, Jean-François, additional, Peschaud, Frédérique, additional, Capper, David, additional, Blons, Hélène, additional, Zimmermann, Ute, additional, Clerici, Thierry, additional, Saiag, Philippe, additional, and Emile, Jean-François, additional

Published
2013
Full Text
View/download PDF

13. Prognostic value of BRAFV600 mutations in melanoma patients after resection of metastatic lymph nodes.

Author

Saiag, Philippe, primary, Moreau, Stephanie, additional, Aegerter, Philippe, additional, Bosset, Daphne, additional, Longvert, Christine, additional, Helias-Rodzewicz, Zofia, additional, Marin, Cristi, additional, Peschaud, Frederique, additional, Chagnon, Sophie, additional, Zimmermann, Ute, additional, Clerici, Thierry, additional, and Emile, Jean-François, additional

Published
2012
Full Text
View/download PDF

14. Anti-HPV16 E2 Protein T-Cell Responses and Viral Control in Women with Usual Vulvar Intraepithelial Neoplasia and Their Healthy Partners

Author

Jacobelli, Simon, primary, Sanaa, Fedoua, additional, Moyal-Barracco, Micheline, additional, Pelisse, Monique, additional, Berville, Sophie, additional, Villefroy, Pascale, additional, North, Marie Odile, additional, Figueiredo, Suzanne, additional, Charmeteau, Bénédicte, additional, Clerici, Thierry, additional, Plantier, Françoise, additional, Arnold, Françoise, additional, Touzé, Antoine, additional, Dupin, Nicolas, additional, Avril, Marie-Françoise, additional, Guillet, Jean-Gérard, additional, Cheynier, Rémi, additional, and Bourgault-Villada, Isabelle, additional

Published
2012
Full Text
View/download PDF

16. Spontaneous Regression of Grade 3 Vulvar Intraepithelial Neoplasia Associated with Human Papillomavirus-16–Specific CD4+ and CD8+ T-Cell Responses

Author

Villada, Isabelle Bourgault, primary, Barracco, Micheline Moyal, additional, Ziol, Marianne, additional, Chaboissier, Aude, additional, Barget, Nathalie, additional, Berville, Sophie, additional, Paniel, Bernard, additional, Jullian, Eric, additional, Clerici, Thierry, additional, Maillère, Bernard, additional, and Guillet, Jean Gérard, additional

Published
2004
Full Text
View/download PDF

17. Prognostic Value of BRAF Mutations in Melanoma Patients After Resection of Metastatic Lymph Nodes.

Author

Moreau, Stéphanie, Saiag, Philippe, Aegerter, Philippe, Bosset, Daphné, Longvert, Christine, Hélias-Rodzewicz, Zofia, Marin, Cristi, Peschaud, Frédérique, Chagnon, Sophie, Zimmermann, Utte, Clerici, Thierry, and Emile, Jean-François

Abstract

Purpose: BRAF mutations are frequent in melanomas, and BRAF-targeted therapy have dramatic, but often transitory, efficacy in stage IV patients. Prognosis of patients with American Joint Committee on Cancer (AJCC) stage III melanoma is heterogeneous. We aimed to determine the overall survival (OS) of stage III patients with a nodal deposit of ≥2 mm according to BRAF mutations and other previously reported prognostic criteria. Methods: This retrospective study included 105 consecutive patients with stage III cutaneous melanomas. Most patients underwent a prospective follow-up. BRAF mutations were detected by sequencing and pyrosequencing of DNA in samples containing >60 % melanoma cells. Results: BRAF mutations (p.V600E and p.V600K in 83 and 14 % of cases, respectively) were detected in 40 % of the patients. For patients with and without BRAF mutations, death occurred in 83.3 and 60.3 %, with a median OS of 1.4 and 2.8 years, respectively. Patient age, primary melanoma ulceration, number of invaded lymph nodes, AJCC staging at study entry, and BRAF status were linked to OS in the univariate analysis. The only characteristics associated with OS in the multivariate analysis were number of invaded lymph nodes ( P = 0.005, hazard ratio 2.2, 95 % confidence interval 1.3-3.9) and BRAF status ( P = 0.005, hazard ratio 1.9, 95 % confidence interval 1.2-3.1). Conclusions: BRAF status could be used to stage melanoma patients with nodal deposits. Our results may also help to plan adjuvant trials in these patients, for whom the low tumor load may induce longer efficacy of BRAF-targeted therapies. [ABSTRACT FROM AUTHOR]

Published
2012
Full Text
View/download PDF

18. Detection of BRAFp.V600E Mutations in Melanomas

Author

Colomba, Emeline, Hélias-Rodzewicz, Zofia, Von Deimling, Andreas, Marin, Cristi, Terrones, Nathalie, Pechaud, Dominique, Surel, Sylvie, Côté, Jean-François, Peschaud, Frédérique, Capper, David, Blons, Hélène, Zimmermann, Ute, Clerici, Thierry, Saiag, Philippe, and Emile, Jean-François

Abstract

BRAF p.V600 mutation detection recently became necessary to treat metastatic melanoma patients with vemurafenib. This study compares different methods of detection of BRAFmutations. Melanoma samples from 111 patients were analyzed for BRAFmutations, and for 89 of them, results were obtained with the four following methods: Sanger sequencing, real-time PCR, immunohistochemistry, and pyrosequencing. All samples contained at least 60% of tumor cells. Directional Sanger sequencing of PCR products failed to detect 3 of 40 p.V600E-mutated cases (7.5%) (sensitivity, 92.5%; 95% CI, 78.5% to 98.0%). BRAFp.V600E-specific real-time PCR identified 39 of 40 p.V600E-mutated cases (97.6%) (sensitivity, 97.5%; 95% CI, 87.1% to 99.6%) and all 39 wild-type (WT) cases and surprisingly was also positive for 6/6 p.V600K (specificity, 87.8%; 95% CI, 75.8% to 94.3%). However, other mutations, p.V600R (n= 1), p.K601E (n= 2), and p.600_601delinsE (n= 1), were not detected. Immunohistochemistry with VE1, specific for p.V600E, identified all p.V600E and WT cases (sensitivity, 100%; 95% CI, 91.2% to 100%) but was negative for all other BRAFmutations. Pyrosequencing successfully identified all WT and mutated cases. Immunohistochemistry is highly specific for p.V600E, and could be used as a first-line method, as is currently performed for HER2amplification detection. Pyrosequencing proved to be the most efficient method to detect BRAFmutations in melanomas and could be performed on VE1-negative or uninterpretable cases.

Published
2013
Full Text
View/download PDF

20. Two Divergent Findings in TEN-Reply

Author

Villada, Gabriel, Roujeau, Jean-Claude, Bourgault, Isabelle, Revuz, Jean, and Clerici, Thierry

Abstract

IN REPLY.— We thank Dr Koff for pointing to some differences between the results of several recent studies on the immunopathology of toxic epidermal necrolysis (TEN). As did other investigators, we observed the abnormal expression of HLA-DR by keratinocytes, a dermal infiltrate composed of T lymphocytes, mainly CD4+, and the absence of cells with a phenotype of natural killer cells.1 The main difference concerns the nature of the epidermal infiltrate. We observed a similar number of CD4+ and CD8+ mononuclear cells within the epidermis, while other investigators reported that all or most of the cells in the epidermis were CD8+.2,3We suggest that these divergent findings resulted less from different case definition than from the different timing of the biopsies. We obtained biopsy specimens from "early" erythematous lesions, distinct from the areas of epidermal sloughing. Our pathologic samples exhibited little or no morphologic alteration of epidermal cells, in contrast

Published
1992
Full Text
View/download PDF

21. Spontaneous regression of grade 3 vulvar intraepithelial neoplasia associated with human papillomavirus-16-specific CD4(+) and CD8(+) T-cell responses.

Author

Bourgault Villada I, Moyal Barracco M, Ziol M, Chaboissier A, Barget N, Berville S, Paniel B, Jullian E, Clerici T, Maillère B, and Guillet JG

Subjects
Adult, Amino Acid Sequence, Carcinoma in Situ immunology, Carcinoma in Situ pathology, Carcinoma in Situ virology, Female, Humans, Lymphocyte Activation immunology, Middle Aged, Molecular Sequence Data, Oncogene Proteins, Viral immunology, Papillomavirus E7 Proteins, Papillomavirus Infections complications, Peptide Fragments immunology, Repressor Proteins immunology, Vulvar Neoplasms pathology, CD4-Positive T-Lymphocytes immunology, CD8-Positive T-Lymphocytes immunology, Neoplasm Regression, Spontaneous immunology, Papillomaviridae immunology, Papillomavirus Infections immunology, Vulvar Neoplasms immunology, Vulvar Neoplasms virology
Abstract

Cell-mediated immunity directed against human papillomavirus 16 (HPV-16) antigens was studied in six patients affected with grade 3 vulvar intraepithelial neoplasia (VIN3, also known as bowenoid papulosis). Five of the patients presented with a chronic and persistent disease that relapsed after destructive treatments. They showed no detectable anti-HPV blood T-cell responses and no T-cell intraepidermal vulvar infiltrate containing both CD4+ and CD8+ lymphocytes. The last patient had a complete clearance of viral lesions, 8 months after disease onset and 2 months after electrocoagulation of <50% of the VIN3 lesions. She showed high frequency anti-E6 and anti-E7 effector blood T cells by ex vivo ELISpot-IFNgamma assay before clinical regression. Immunohistochemical study of her vulvar biopsy revealed a marked dermal infiltrate containing a majority of CD4+ T lymphocytes and an epidermal infiltrate made up of both CD4(+) and CD8(+) T cells. This seems to be the first evidence of an association between spontaneous regression of VIN3 lesions and HPV-specific T-cell responses detectable in the blood. Hence, an increase of HPV-specific effector T lymphocyte responses by vaccine-based therapeutic strategies might be useful to clear the lesions in bowenoid papulosis disease.

Published
2004
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results